Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 18, 2008 - Issue 8
Submit an article Journal homepage
170
Views
24
CrossRef citations to date
0
Altmetric
Review

Very late antigen-4 integrin antagonists

Jefferson W Tilley Senior Research Director Hoffmann-La Roche, Inc., Roche Research Center, 340 Kingsland Street, Nutley, NJ 07110, USA +1 973 235 4660; +1 973 235 6084;[email protected]
Pages 841-859 | Published online: 04 Aug 2008

Bibliography

  • Erle DJ, Briskin MJ, Butcher EC, et al. Expression and function of the MAdCAM-1 receptor, integrin α4β7, on human leukocytes. J Immunol 1994;153:517-28
  • Henderson RB, Lim LHK, Tsessier PA, et al. The use of lymphocyte function-associated antigen deficient mice to determine the role of LFA-1, Mac-1 and α4 integrin in the inflammatory response of neutrophils. J Exp Med 2001;194:219-26
  • Gao J-X, Issekutz AC. The beta1 integrin, very late activation antigen-4 on human neutrophils can contribute to neutrophil migration through connective tissue fibroblast barriers. Immunology 1997;90:448-54
  • Van den Berg J, Merlijn J, Mul FPJ, et al. Beta 1 integrin activation on human neutrophils promotes beta2-mediated adhesion to fibronectin. Eur J Immunol 2001;31:276-84
  • Newham P, Craig SE, Seddon GN, et al. Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. J Biol Chem 1997;272:19429-40
  • Jones EY, Harlos K, Bottomley MJ, et al. Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 Å resolution. Nature 1995;373:539-44
  • Komoriya A, Green IJ, Mervi M, et al. The minimal essential sequence for a major cell type-specific adhesion site (CS-1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J Biol Chem 1991;266:15075-9
  • Jongewaard IN, Tsai PM, Smith JW. The type III connecting segment of fibronectin contains an aspartic acid residue that regulates the rate of binding to integrin α4β1. Cell Adhesion Comm 1996;3:487-95
  • Briskin M, Winson-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110
  • Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukcyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-89
  • Arnaout MA, Mahalingam B, Xiong J-P. Integrin structure, allostery and bidirectional signaling. Ann Rev Cell Dev Biol 2005;21:381-410
  • Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Ann Rev Cell Dev Biol 1995;11:549-99
  • Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev 2007;218:126-34
  • Xiong J-P, Stehle T, Diffenbach B. Crystal structure of the extracellular segment of integrin alphavbeta3. Science 2001;294:339-45
  • Xiong J-P, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 2002;296:151-5
  • Chigaev A, Waller A, Zwartz GJ, et al. Regulation of cell adhesion by affinity and conformational unbending of alpha4beta1 integrin. J Immunol 2007;178:6828-39
  • Lou B-H, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Ann Rev Immunol 2007;25:619-47
  • Takagi J. Structural basis for ligand recognition by integrins. Curr Opin Cell Biol 2007;19:557-64
  • Arnaout MA, Goodman SL, Xiong J-P. Structure and mechanics of integrin based cell adhesion. Curr Opin Cell Biol 2007;19:495-507
  • Tilley JW. VLA antagonists. Expert Opin Ther Patents 2002;12:991-1008
  • Bosserhoff A-K. Integrins as targets in therapy. Expert Opin Ther Patents 2006;16:963-75
  • Davenport RJ, Munday JR. Alpha4 – integrin antagonism – an effective approach for the treatment of inflammatory diseases? Drug Discov Today 2007;12:569-76
  • Tilley JW, Chen L, Sidduri A, Fotouhi N. The discovery of VLA4 antagonists. Curr Top Med Chem 2004;4:1509-23
  • Huryn DM, Konradi AW, Ashwell S, et al. The identification and optimization of orally efficacious, small molecule VLA4 antagonists. Curr Top Med Chem 2004;4:1473-84
  • Pacheco KA, Tarkowski M, Klemm J, Rosenwasser LJ. CD49d expression and function on allergen-stimulated T cells from blood and airway. Am J Respir Cell Mol Biol 1998;18:286-93
  • Bocchino V, Bertorelli G, D'Lppolito R, et al. The increased number of very late activation-4 positive cells correlates with eosinophils and severity of disease in the induced sputum of asthmatic patients. J Allergy Clin Immunol 2000;105:65-70
  • MacKay IR, Rosen FS. T-cell function and migration. N Engl J Med 2000;343:1020-34
  • Berlin C, Bargatze RF, Campbell JJ, et al. α4 Integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995;80:413-22
  • Johnston B, Issekutz TB, Kubes P. The alpha4-integrin supports leukocyte rolling and adhesion in chronically inflamed postcapillary venules in vivo. J Exp Med 1996;183:1995-2006
  • Vanderslice P, Woodside DG. Integrin antagonists as therapeutics for inflammatory diseases. Expert Opin Investig Drugs 2006;15:1235-55
  • Barthel AR, Johansson MW, McManee DM, Mosher DF. Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukocyte Biol 2008;83:1-12
  • Pablo AJ, Hallgren J, Jones T, et al. Alpha-4 integrins and VCAM-1, but not MAdCAM-1 are essential for recruitment of mast cell progenitors to the inflamed lung. Blood 2006;108:1588-94
  • Ohkawara Y, Yamauchi K, Maruyama N, et al. In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with airflow limitation: in vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration. Am J Respir Cell Mol Biol 1995;12:4-12
  • Zangrilli JG, Shaver JR, Cirelli RA, et al. VCAM-1 levels after segmental challenge correlate with eosinophil influx and IL-4 and IL-5 production, and the late phase response. Am J Respir Crit Care Med 1995;151:1346-53
  • Lin KC, Ateeq HS, Hsiung SH, et al. Selective tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J Med Chem 1999;42:920-34
  • Abraham WM, Gill A. Ahmed A, et al. A small molecule, tight binging inhibitor of the integrin alpha4beta1 blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med 2000;162:603-11
  • Chen LL, Whitty A, Lobb RR, et al. Multiple activation states of integrin α4β1 detected through their different affinities for a small molecule ligand. J Biol Chem 1999;274:13167-75
  • Norris V, Choong L, Tran D, et al. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 2005;116:761-7
  • Diamant Z, Kuperus J, Baan R, et al. Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin Exp Asthma 2005;35:1080-7
  • An inhaled VLA4 antagonist. Exp Opin Ther Patents 2002;12:755-7
  • Ravensberg AJ, Luijk B, Westers P, et al. The effect of a single dose of a VLA-4 antagonist on allergen-induced airways responses and airway inflammation in patients with asthma. Allergy 2006;61:1097-103
  • Hijazi Y, Welker H, Dorr AE, et al. Pharmacokinetics, safety and tolerability of R411, a dual a4b1 alpha4beta7 integrin antagonist after oral administration at single and multiple once daily ascending doses in healthy volunteers. J Clin Pharmacol 2004;44:1368-78
  • Tilley J, Sidduri A, Chen L, et al. Discovery of R411: a VCAM/VLA4 antagonist for the treatment of asthma. Abstracts of papers, 234th ACS National Meeting; 2007 August 19 – 23; MEDI250
  • Sircar I, Gudmundsson KS, Martin R, et al. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha4beta1- alpha4beta7 integrin antagonist. Bioorg Med Chem 2002;10:2051-66
  • Cortijo J, Sanz M-J, Iranzo A, et al. A small molecule, orally active, a 4b 1/a 4b 7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. Br J Pharmacol 2006;147:661-70
  • Tsuda-Tsukimoto M, Ogasawara Y, Kume T. Pharmacokinetics and metabolism of TR-14035, a novel antagonist of alpha4beta1/alpha4beta7 integrin mediated cell adhesion in rat and dog. Xenobiotica 2005;35:373-89
  • Tsuda-Tsukimoto M, Maeda T, Iwanaga T, et al. Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta17 dual integrin antagonist, TR-14035. Pharm Res 2006;23:2646-56
  • Frohman EM, Racke MK, Raine. Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 2006;354:942-55
  • Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 1999;22:30-8
  • Piraino PS, Yednock TA, Messersmith EK, et al. Spontaneous remyelination following prolonged inhibition of α4 integrin in chronic EAE. J Neuroimmunol 2005;167:53-63
  • Reparon-Schuijt CC, Van Esch WJE, Van Kooten C, et al. Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. Arthritis Rheum 2000;43:1115-21
  • Kitani A, Nakashima N, Izumihara T, et al. Soluble VCAM-1 induces chemotaxis of Jurkat and synovial fluid T cells bearing high affinity very late antigen-4. J Immunol 1998;161:4931-8
  • Tokuhira M, Hosaka S, Volin MV, et al. Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 2000;43:1122-33
  • Silverman MD, Haas CS, Rad AM, et al. The role of vascular cell adhesion molecule 1/very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum 2007;56:1817-26
  • Seiffge D. Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. J Rheumatol 1996;23:2086-91
  • Carter RA, Wicks IP. Vascular cell adhesion molecule 1 (CD 106): a multifaceted regulator of joint inflammation. Arthritis Rheum 2001;44:985-94
  • Natalizumab in the treatment of rheumatoid arthritis in subjects receiving methotrexate. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT00083759?spons=%22Elan+ Pharmaceuticals%22&spons_ex=Y&rank=9
  • Brandtzaeg P, Haraldsen G, Helgeland L, et al. New insights into the immunopathology of human inflammatory bowel disease. Drugs Today 1999;35(Suppl A, Crossing Borders in IBD):33-70
  • Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut homing integrin alpha4beta7. Gastroenterology 1996;111:1373-80
  • Kato S, Hokari R, Matsuzaki K, et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther 2000;295:183-9
  • Picarella D, Hurlbut P, Rottman J, et al. Monoclonal antibodies specific for beta7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of SCID mice reconstituted with CD45RB high CD4+ T cells. J Immunol 1997;158:2099-106
  • Soriano A, Salas A, Salas A. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 2000;80:1541-51
  • Papayannopoulou T, Craddock C, Nakamoto B, et al. The VLA-4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995;92:9647-51
  • Chan JYH, Watt SM. Adhesion receptors on haematopoietic progenitor cells. Br J Haemtol 2001;112:541-57
  • Weekes CD, Kuszynski CA, Sharp JG. VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leuk Lymphoma 2001;40:631-45
  • Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha4beta1 integrin enhances production of osteoclast-stimulating activity. Blood 2000;96:1953-60
  • Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67
  • Kwee L, Baldwin HS, Shen HM, et al. Defective development of the embryonic and extra embryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development 1995;121:489-503
  • Gurtner GC, Davis V, Li H, et al. Targeted disruption of the murine VCAM-1 gene: essential role of VCAM-1 in chorioallontoic fusion and placentation. Genes Dev 1995;9:1-14
  • Crofts E, Pino M, DeLise B, et al. Different embryo-fetal toxicity effects for three VLA-4 antagonists. Birth Defects Res B 2004;71:55-68
  • Crofts E, Rohatagi S, Pino M, et al. Critical period for a teratogenic VLA-4 antagonist: development effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists. Birth Defects Res B 2004;71:69-79
  • Spence S, Vetter C, Hagmann WK, et al. Effects of VLA-4 antagonists in rat whole embryo culture. Teratology 2002;65:26-37
  • Léger OJP, Yednock TA, Tanner L, et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997;8:3-16
  • Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005;4:510-9
  • O'Connor P. Natalizumab and the role of α4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther 2007;7:123-36
  • Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
  • Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta 1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
  • Khalili K, White MK, Lublin F, et al. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007;68:985-90
  • Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33
  • Biogen Idec. COMPANY communication concerning the lack of new cases of PML as of March 2008. Available from: http://www.biogenidec.com/site/tysabri-information-center.html
  • A description of the ‘TYGRIS’ trial. Available from: http://clinicaltrials.gov/ct2/show/NCT00483847?spons=%22Elan+Pharmaceuticals%22&spons_ex=Y&rank=28
  • Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
  • Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's Disease: results of the ENCORE trial. Gastroenterology 2007;132:1672-83
  • Full prescribing information and efficacy data of nataizumab in Crohn's disease. Available from: http://www.tysabri.com/tysbProject/tysb.portal/_baseurl/twoColLayout/SCSRepository/en_US/tysb/home/product-information/index.html
  • Joint meeting of the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held on 31 July 2007: agenda, minutes and presentation slides. Available from: http://www.fda.gov/ohrms/dockets/ac/cder07.htm#gdac
  • Dear Health Care professional letter concerning potential hepatotoxicity associated with natalizumab. Available from: http://www.fda.gov/medwatch/safety/2008/tysabri_dhcp_letter.pdf
  • Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008;358:647-8
  • Anthoni D, Rijcken E, Mennigen R, et al. Inhibition of leukocyte-endothelial interaction by antisense oligonucleotides against VCAM-1 in a rat model of inflammatory bowel disease. Chir Forum Exp Klin Forsch 2001;179-81
  • Myers KJ, Witchell DR, Graham MJ, et al. Antisense oligonucleotide blockade of α 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 2005;160:12-24
  • ISIS Pharmaceuticals. Antisense modulation of integrin alpha4 expression. US6258790; 2001
  • Antisense Therapeutics Ltd. Antisense modulation of integrin alpha4 expression. WO2006086821; 2006
  • Antisense Therapeutics update of status of development and sub-licensing of ATL-1102. Available from: http://www.antisense.com.au/_home.asp
  • Tanabe Seiyaku Co. Inhibitors of alpha4 mediated cell adhesion. WO0218320
  • Tanabe Seiyaku Co. Process for preparing a phenylalanine derivative and intermediates thereof. WO03072536
  • A listing of current and terminated clinical trials involving compound 13. Available from: http://www.clinicaltrials.gov/ct2/results?term=&recr=&type=&cond=multiple+sclerosis&intr=&spons=glaxosmithkline&id=&state1=&cntry1=&state2=&cntry2= &state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e=
  • Celltech R&D Ltd. Preparation of phenylalanine enamide derivatives possessing a cyclobutene group for use as integrin inhibitors. WO2002068393; 2002
  • A UCB press release announcing commencement of phase 2 clinical trials for compound 14. Available from: http://www.ubc-group.com/investor_relations/2530.htm
  • Celltech R&D. Process for the preparation of phenylalanine enamide derivatives. WO2004007428
  • Celltech R&D. Preparation of phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors. WO2004007494; 2004
  • Celltech R&D. Preparation of phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors. WO2004006918; 2004
  • Ajinomoto Co., Inc. Preparation of novel phenylalanine derivatives having a4 integrin-inhibitory activity. WO20022016329; 2006
  • Ajinomoto Co., Inc. Process for preparation of phenylalanine derivatives having quinazoline skeleton. WO2004074264; 2004
  • Ajinomoto Co., Inc. Crystal of phenylalanine derivative and process for producing same. WO2005051925; 2005
  • Ajinomoto Co., Inc. Sustained-release phenylalanine derivative preparation for oral administration. WO2005046697; 2005
  • Ajinomoto Co., Inc. Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative. WO2005046696; 2005
  • Ranbaxy Laboratories Ltd. Preparation of arylaminocarbonylaminotriazinamino acids as inhibitors of cell adhesion for the treatment of inflammatory and autoimmune diseases. WO2005030735; 2005
  • Gläsner J, Blum H, Wehner V, et al. A small molecule α4β1 antagonist prevents development of murine Lyme arthritis without affecting protective immunity. J Immunol 2005;175:4724-34
  • Tanabe Seiyaku Co. Preparation of 2-(phenylmethyl)pyrimidinones and related compounds as alpha-4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases. WO2005075438; 2005
  • Tanabe Seiyaku Co. Pharmaceutical compositions containing alpha-4 integrin mediated cell adhesion inhibitors. JP2007063268; 2007
  • Witherington J, Bordas V, Gaiba A, et al. Pyridone derivatives as potent and selective VLA-4 integrin antagonists. Bioorg Med Chem Lett 2006;16:2256-9
  • Witherington J, Blaney EL, Bordas V, et al. Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists. Bioorg Med Chem Lett 2006;16:5538-41
  • Liu R, Peng L, Lam KS. Structure-activity relationship studies of a series of peptidomimetic ligands of alpha4beta1 integrin on Jurkat T-leukemia cells. Biopolymers 2006;84:595-604
  • Li P, Liu R, Marik J, et al. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2006;2:381-9
  • Carpender RD, Andrei M, Lau FC, et al. Highly potent, water soluble benzimidazole antagonist for activated α4β1 integrin. J Med Chem 2007;50:5863-7
  • Chiba J, Machinaga N, Takashi T, et al. Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist. Bioorg Med Chem Lett 2005;15:41-5
  • Chiba J, Iimura S, Yoneda Y, et al. 4-(Pyrrolidinyl)methoxybenzoic acid derivatives as a potent, orally active VLA-4 antagonist. Chem Pharm Bull 2006;54:1515-29
  • Daiichi Pharmaceutical Co. VLA-4 inhibitor compounds. WO0100206; 2001
  • Chiba J, Iimura S, Yoneda Y, et al. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem 2007;15:1679-93
  • Ito T, Takahashi M, Sudo K, Sugiyama Y. Marked strain differences in the pharmacokinetics of an alpha4beta1 integrin antagonist, 4-[1-[3-chloro-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]methoxybenzoic acid (D01-4582), in Sprague-Dawley rats are associated with albumen genetic polymorphism. J Pharmacol Exp Ther 2007;320:124-32
  • Chiba J, Takayama G, Takashi T, et al. Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists. Bioorg Med Chem 2006;14:2725-46
  • Daiichi Pharmaceuticals Co. Preparation of N-(phenylacetyl- or 2-pyridylacetyl)pyrrolidine derivatives as very late antigen-4 (VLA-4) inhibitory drugs. WO2007069635; 2007
  • Daiichi Pharmaceuticals Co. VLA-4 inhibitor. WO2005121135; 2005
  • Sedgwick JB, Jansen KJ, Kennedy JD, et al. Effects of the very late adhesion molecule 4 antagonist WAY103 on human peripheral blood eosinophil vascular cell adhesion molecule 1-dependent functions. J Allergy Clin Immunol 2005;116:812-9
  • Huryn DM, Ashwell S, Baudy R, et al. Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists. Bioorg Med Chem Lett 2004;14:1651-4
  • Elan Pharmaceuticals, Inc. Preparation of sulfonyl dipeptides for treatment of demyelinating diseases an paralysis. WO2004066932; 2004
  • Elan Pharmaceuticals, Inc. Multimeric VLA-4 antagonists comprising polymer moieties. US20060013799; 2006
  • Athena Neurosciences, Inc. Alpha-9 integrin antagonists and anti-inflammatory compositions thereof. WO9906391; 1999
  • Merck & Co. VLA-4 Antagonists. WO2006113199; 2006
  • Merck. Preparation of prolylphenylalanine derivatives as VLA-4 antagonists. WO2005087760; 2005
  • Merck & Co. VLA-4 antagonists. WO2006115918; 2006
  • Merck & Co. VLA-4 antagonists. WO2006023396; 2006
  • Dyatkin AB, Hoekstra WJ, Kinney WA, et al. Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists. Bioorg Med Chem Lett 2004;14:591-6
  • Dyatkin AB, Gong Y, Miskowski ES, et al. Aza-bicyclic amino acid carboxamides as alpha4-beta1/alpha4beta7 integrin receptor antagonists. Bioorg Med Chem 2005;13:6693-702
  • Lawson EC, Santulli RJ, Dyatkin AB, et al. Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent. Bioorg Med Chem 2006;14:4208-16
  • Merck & Co. Subsituted amidine derivatives as inhibitors of cell adhesion. US6734311; 2003
  • Ranbaxy Laboratories Ltd. Preparation of dioxolane derivatives as cell adhesion inhibitors with therapeutic uses. WO2005026163; 2005
  • Ranbaxy Laboratories Ltd. Isoxazole derivatives as cell adhesion inhibitors and their preparation and pharmaceutical composition. WO2006090234; 2006
  • Okigami H, Takeshita K, Tajimi M, et al. Inhibition of eosinophilia in vivo by a small molecule inhbitor of very late antigen (VLA)-4. Eur J Pharmacol 2007;559:202-9
  • Yoichiro H, Ikegami S, Okuyama A, et al. 2,3-Diphenylpropionic acids as potent VLA-4 antagonists. Bioorg Med Chem Lett 2005;15:217-20
  • Yoichiro H, Ikegami S, Fujimoto K, et al. Solid-phase synthesis of 2,3-diphenylpropionic acid library as VLA-4 antagonists. Tet Lett 2005;46:9035-8
  • Elan Pharmaceuticals. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4. WO2007101165; 2007
  • Elan Pharmaceuticals. Compounds which inhibit leukocyte adhesion mediated by VLA-4. WO2007041324; 2007
  • Elan Pharmaceuticals. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4. WO2007041270; 2007
  • Almirall Prodesfarma SA. N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists. WO2004099126; 2004
  • Celltech R&D. Preparation of phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors. WO2004006918; 2004
  • Tilley JW, Sidduri A, Lou JP, et al. Indentification of N-acyl-4-(3-pyidinyl)phenylalanine derivatives and their orally active prodrug esters as dual acting alpha4-beta1 and alpha4-beta7 receptor antagonists [abstract MEDI-426]. 234th ACS National Meeting; 2007 Aug 19 – 23; Boston, USA
  • Ajinomoto Co., Inc. Phenylalanine derivatives with the ability to inhibit alpha4 integrin-mediated adhesion. WO03053926; 2003
  • Ajinomoto Co., Inc. Novel phenylalanine derivatives. US20050222141; 2005
  • Ajinomoto Co., Inc. Crystal of phenylalanine derivative, process for producing the same and use thereof. WO2006137450; 2006
  • Gong Y, Barbay JK, Kimball ES, et al. Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists. Bioorg Med Chem Lett 2008;18:1331-5
  • Gong Y, Barbay JK, Dyatkin AB, et al. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists. J Med Chem 2006;49:3402-11
  • Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives as VLA-4 antagonists. WO2006127584; 2006
  • Lassoie M-A, Broeders F, Collart P, et al. 2,6-Quinolinyl derivatives as potent VLA-4 antagonists. Bioorg Med Chem Lett 2007;17:142-6
  • Saku O, Ohta K, Arai E, at al. Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationships of piperazinylphenylalanine derivatives. Bioorg Med Chem Lett 2008;18:1053-7
  • Lawson EC, Kinney WA, Santulli RJ, et al. Synthesis and biological evaluation of 1,2,4-triazolo[2,3-a]pyrrole derivatives as alpha-4 (a4) integrin antagonists. Lett Drug Des Discov 2005;2:601-5
  • Janssen Pharmaceuticals NV. Preparation of bicyclic triazole amino acid derivatives as alpha4 integrin inhibitors. WO2006052962; 2006
  • Venkatraman S, Lim J, Cramer M, et al. Influence of acid surrogates toward potency of VLA-4 antagonist. Bioorg Med Chem Lett 2005;15:4053-6
  • Chang LL, Yang GX, McCauley E, et al. Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists. Bioorg Med Chem Lett 2008;18:1688-91
  • Chang LL, Truong Q, Doss GA, et al. Highly constrained bicyclic VLA-4 antagonists. Bioorg Med Chem Lett 2007;17:597-601
  • Encysive Pharmaceuticals, Inc., Schering Corp. Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds. WO2004044046; 2004
  • Encysive Pharmaceuticals, Inc. Carboxylic acids derivatives that inhibit the binding of integrins to their receptors. US2004063955; 2004

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.